BofA analyst Travis Steed upgraded Edwards Lifesciences to Buy from Neutral.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Bad News for Edwards Lifesciences Corp. Stock: This New Risk Has Been Added
- Edwards Lifesciences price target raised to $100 from $90 at Barclays
- Edwards Lifesciences price target raised to $86 from $64 at Deutsche Bank
- Edwards Lifesciences price target raised to $95 from $82 at RBC Capital
- Edwards Lifesciences price target raised to $86 from $81 at Canaccord